These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22541034)

  • 1. [Anticoagulants and dual antiplatelet therapy combined, a challenge to our intelligence].
    Morais J
    Rev Port Cardiol; 2012 Apr; 31 Suppl 1():38-44. PubMed ID: 22541034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes.
    Tsu LV; Dager WE
    Ann Pharmacother; 2013 Apr; 47(4):573-7. PubMed ID: 23548645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy in hospitalized patients: facts and controversies.
    Srour JF; Smetana GW
    J Hosp Med; 2011 Nov; 6(9):537-45. PubMed ID: 21374797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
    Gibson CM; Chakrabarti AK; Mega J; Bode C; Bassand JP; Verheugt FW; Bhatt DL; Goto S; Cohen M; Mohanavelu S; Burton P; Stone G; Braunwald E;
    J Am Coll Cardiol; 2013 Jul; 62(4):286-90. PubMed ID: 23602776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
    Krantz MJ; Kaul S
    J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antiplatelet and anticoagulant agents in the cardiac care unit.
    Garg VP; Halperin JL
    Cardiol Clin; 2013 Nov; 31(4):533-44, viii. PubMed ID: 24188219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome.
    Camuglia AC; Waddell-Smith KE; Hammett CJ; Aylward PE
    Curr Med Res Opin; 2014 Nov; 30(11):2151-67. PubMed ID: 25140867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban (Xarelto) for acute coronary syndrome.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):97. PubMed ID: 22173426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
    Kar S; Bhatt DL
    Coron Artery Dis; 2012 Sep; 23(6):380-90. PubMed ID: 22728913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
    Ahrens I; Bode C
    Future Cardiol; 2012 Jul; 8(4):533-41. PubMed ID: 22871192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
    Depta JP; Cannon CP; Fonarow GC; Zhao X; Peacock WF; Bhatt DL;
    Am J Cardiol; 2009 Nov; 104(9):1171-8. PubMed ID: 19840557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
    Norgard NB; Dinicolantonio JJ
    Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group.
    Staritz P; de Moerloose P; Schutgens R; Dolan G;
    Haemophilia; 2013 Nov; 19(6):833-40. PubMed ID: 23710576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.
    Davis EM; Packard KA; Knezevich JT; Campbell JA
    Pharmacotherapy; 2011 Oct; 31(10):975-1016. PubMed ID: 21950643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oral anticoagulants in the ED setting: a review.
    Pollack CV
    Am J Emerg Med; 2012 Nov; 30(9):2046-54. PubMed ID: 22795419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
    Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.
    Aalbers J
    Cardiovasc J Afr; 2012 Oct; 23(9):525-6. PubMed ID: 23108522
    [No Abstract]   [Full Text] [Related]  

  • 20. Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
    Ice DS; Shapiro TA; Gnall EM; Kowey PR
    Am J Cardiol; 2014 Mar; 113(5):888-96. PubMed ID: 24528617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.